WaveMan
WaveMan · Company
PTHS · Pelthos Therapeutics Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PTHS Pelthos Therapeutics (PTHS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001919246
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
16
13F, latest reported quarter

What the filings say about PTHS

Insiders, 180 days
+$851.0K net bought
1 buyer · 4 sellers · 25% of sales under a 10b5-1 plan

Pelthos Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Pelthos Therapeutics Inc. insiders bought a net $851.0K of stock across 26 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Friedberg Ezra M
Director
SELL
2026-10-06 SECtraded 2026-10-02
558
$11.6K
-27.6%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jul 2, 2026.
  • The trade is 0.7% of the 80,484 shares held after it.
  • 2 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Friedberg Ezra M sold about $11.6K of PTHS under a 10b5-1 plan on Oct 2, 2026; 2 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
Pauls Matthew
Director
SELL
2026-10-06 SECtraded 2026-10-02
786
$16.5K
-27.6%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jul 2, 2026.
  • The trade is 5.8% of the 13,578 shares held after it.
  • 2 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pauls Matthew sold about $16.5K of PTHS under a 10b5-1 plan on Oct 2, 2026; 2 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
Greenleaf Peter
Director
SELL
2026-10-06 SECtraded 2026-10-02
797
$16.9K
-27.6%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jul 2, 2026.
  • The trade is 3.5% of the 23,087 shares held after it.
  • 2 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Greenleaf Peter sold about $16.9K of PTHS under a 10b5-1 plan on Oct 2, 2026; 2 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
Friedberg Ezra M
Director
SELL
2026-07-07 SECtraded 2026-07-02
534
$13.9K
-45.7%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jun 15, 2026.
  • The trade is 0.7% of the 81,066 shares held after it.
  • 2 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Friedberg Ezra M sold about $13.9K of PTHS on Jul 2, 2026; 2 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
Friedberg Ezra M
Director
SELL
2026-07-07 SECtraded 2026-07-02
24
$656
-45.7%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jun 15, 2026.
  • The trade is 0.0% of the 81,042 shares held after it.
  • 2 other insiders sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Friedberg Ezra M sold about $656 of PTHS on Jul 2, 2026; 2 other insiders sold within 30 days and 16 funds added in the latest 13F quarter.
26 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 21 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$851.0K over 180 days
-$44.9K over 90 days
more than 87% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
16 funds bought in last quarter
below 72% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-257.9% net margin
below 70% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.7% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
below 61% of Pharma & Biotech
What changed in the last 30 days
Oct 6Director Greenleaf Peter sold $16.9K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6Director Pauls Matthew sold $16.5K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6Director Friedberg Ezra M sold $11.6K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch PTHS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-56.1%12M
-56%-35%-13%+8%2025-102025-122026-022026-042026-062026-082026-10 2026-06-11 · Davis Todd C bought $985.4K2025-11-25 · Friedberg Ezra M sold $168.0K2025-11-25 · Friedberg Ezra M sold $56.3K2025-11-25 · Friedberg Ezra M sold $56.0K2026-05-22 · Francis Knuettel II sold $40.3K2026-07-02 · Greenleaf Peter sold $18.5K2026-07-02 · Pauls Matthew sold $18.0K2026-10-02 · Greenleaf Peter sold $16.9K2026-10-02 · Pauls Matthew sold $16.5K2026-06-11 · Davis Todd C bought $14.5K2026-07-02 · Friedberg Ezra M sold $13.9K2026-10-02 · Friedberg Ezra M sold $11.6K2026-04-02 · Greenleaf Peter sold $8.6K2026-04-02 · Pauls Matthew sold $8.5K2026-04-02 · Greenleaf Peter sold $8.1K2026-04-02 · Pauls Matthew sold $7.9K2026-04-02 · Malamut Richard sold $6.4K2026-06-15 · Friedberg Ezra M sold $6.1K2026-04-02 · Friedberg Ezra M sold $6.0K2026-04-02 · Malamut Richard sold $6.0K2026-04-02 · Friedberg Ezra M sold $5.7K2026-07-02 · Pauls Matthew sold $2.6K2026-07-02 · Greenleaf Peter sold $2.3K2026-06-15 · Friedberg Ezra M sold $1.6K2026-07-02 · Friedberg Ezra M sold $6562025-11-25 · Friedberg Ezra M sold $28
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PTHS: institutional holders (13F)

13F holdings, latest reported quarter
AIGH Capital Management LLC
329,098 sh
$9.3M
Murchinson Ltd.
304,302 sh
$8.6M
Ikarian Capital, LLC
256,598 sh
$7.3M
BOOTHBAY FUND MANAGEMENT, LLC
101,976 sh
$2.9M
VANGUARD CAPITAL MANAGEMENT LLC
97,134 sh
$2.7M

Congress trades in PTHS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PTHS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PTHS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$141.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$9.4K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$455.8K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$197.6K position · as of 2026-05-31
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$51.4K position · as of 2026-06-30
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$2.2M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $851.0K bought by insiders over 180 days, 16 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PTHS financials

Net margin
-257.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$43.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-199.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.98x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-125.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-116.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$77.3M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$16.8M$0n/an/a
Operating income-$32.4M-$7.6M-$6.9M-$2.3M
Net income-$43.3M-$8.0M-$7.4M-$2.5M
EPS (diluted)-23.04-14.27-5.78n/a
Operating cash flow-$22.6M-$5.8M-$981.0K-$1.6M
Cash$18.0M$513.0K$100.0K$100.0K
Long-term debt$31.4M$0n/an/a
Buybacks$0$75.0Kn/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

PTHS Stock Sonar score 5/7 axes

Find similar shapesCompare

PTHS ranks highest on insider conviction (72nd percentile) and financial health (52nd), and lowest on profitability (20th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
20
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-125.0% · 19 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-116.8% · 21 pct, sector of 576
Financial health
52
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.98x · 52 pct, sector of 371
Insider conviction
72
Inputs
  • Net Form 4 buying (codes P and S), 180d$896K · 87 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
28
Inputs
  • Funds adding, latest quarter16 · 28 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
24
Inputs
  • Short interest, % of float+7.7% · 47 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+81.8% · 2 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PTHS filings, in plain words

Are Pelthos Therapeutics insiders buying or selling PTHS?

In the 180 days to 2026-10-28, Pelthos Therapeutics insiders were net buyers, a net $851.0K: $999.8K of purchases and $148.9K of sales reported on Form 4, by 1 buyer and 4 sellers.

Read the full summary

In the 180 days to 2026-10-28, Pelthos Therapeutics insiders were net buyers of PTHS, a net $851.0K across purchases and sales reported on Form 4 by 1 buyer and 4 sellers. 25% of the 12 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies